112 results
Page 5 of 6
8-K
EX-99.1
3bsl6q u6
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
wt34w jgnkqvmyfxcb8a
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.2
59d1s7ab
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am
8-K
EX-99.1
os7c4n
24 Apr 19
Regulation FD Disclosure
8:31am
8-K
EX-1.1
5h7y dqqr3w28e3
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
6hbm0em998uwe yvgp2
8 Apr 19
Prospectus supplement for primary offering
12:00am
424B5
jfv2bc0bc ox
8 Apr 19
Prospectus supplement for primary offering
12:00am
8-K
EX-1.2
nqemx01rza4n6lx7o
8 Apr 19
Entry into a Material Definitive Agreement
12:00am
424B5
yv3e4qlc 0k05cke24fl
4 Apr 19
Prospectus supplement for primary offering
4:15pm
424B5
qowix1tlu
4 Apr 19
Prospectus supplement for primary offering
4:13pm
8-K
EX-10.1
yprb7k87vrrcvnl1qjs
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-99.2
eoir4djz9kizi
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
62rn7ggl3imeul
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
ewbzwk0v ru134j
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.1
rdi9tsxlcu7279js
3 Dec 18
Syros Announces Promising Clinical Data from Ongoing Phase 2 Trial of SY-1425 in Genomically Defined AML and MDS Patients at ASH Annual Meeting
8:07am
8-K
EX-99.1
yd9vk
15 Nov 18
Regulation FD Disclosure
4:03pm